Alveron Pharma, a Nijmegen, the Netherlands-based company advancing a synthetic anticoagulant and platelet inhibitor reversal agent, raised €5M in Seed extension funding.
The round was led by Broadview Ventures with participation from Sanquin (the Dutch Blood Foundation), Thuja Capital, Waterman Ventures and Oost NL.
The company intends to use the funds to advance its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage (ICH).
Founded in 2019 and led by CEO Ben Nichols, Alveron Pharma is developing a synthetic anticoagulant and platelet inhibitor reversal agent to prevent haematoma expansion and improve clinical outcomes in patients with ICH.
OKL-1111 has a universal mode of action by binding to a downstream clotting factor, enabling administration within 10 minutes of a diagnosing CT scan. In addition, the drug reverses the effects of clopidogrel, a major platelet inhibitor, for which there is currently no antidote.
FinSMEs
09/12/2024